Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
View Full LandscapeTarget Indication
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Clinical Trial
NCT02549170Last updated: 10/25/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Kiovig
Replacement therapy in adults, and children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT); congenital AIDS and recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease; multifocal motor neuropathy (MMN).
View on EMAFabry Disease
Type 2 Diabetes Mellitus
Primary Immunodeficiency Disease
Primary Immunodeficiency Diseases (PID)
Hypertension
